NASDAQ:MGTX MeiraGTx Q3 2025 Earnings Report $10.90 -0.15 (-1.36%) As of 12:56 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast MeiraGTx EPS ResultsActual EPS-$0.62Consensus EPS -$0.50Beat/MissMissed by -$0.12One Year Ago EPSN/AMeiraGTx Revenue ResultsActual Revenue$0.41 millionExpected Revenue$7.71 millionBeat/MissMissed by -$7.30 millionYoY Revenue GrowthN/AMeiraGTx Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time8:00AM ETUpcoming EarningsMeiraGTx's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings Documents MeiraGTx Earnings HeadlinesGoldman Sachs Initiates MeiraGTx at Neutral With $16 Price TargetSeptember 24 at 8:53 AM | marketscreener.comMMeiraGTx Holdings plc Announces Appointment of Alan M. Sebulsky to its Board of DirectorsSeptember 23 at 12:50 PM | marketscreener.comMSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 25 at 1:00 AM | Altimetry (Ad)MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of DirectorsSeptember 23 at 8:00 AM | globenewswire.comMeiraGTx Holdings PLC MGTXSeptember 16, 2026 | morningstar.comMGraviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide PharmaceuticalAugust 26, 2026 | prnewswire.comSee More MeiraGTx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email. Email Address About MeiraGTxMeiraGTx (NASDAQ:MGTX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes to targeted tissues, with an emphasis on disorders affecting the central nervous system, the eye and other organs. MeiraGTx’s pipeline has included botaretigene sparoparvovec, an investigational AAV-based gene therapy for X-linked retinitis pigmentosa caused by mutations in the RPGR gene. The company has also pursued gene therapy programs for neurological and neurodegenerative conditions, including Parkinson’s disease, as well as additional rare and potentially serious diseases. Its research platform includes technologies designed to regulate gene expression, which may help control the timing and amount of therapeutic proteins produced after treatment. Founded in 2015, MeiraGTx operates internationally, with activities in the United States and the United Kingdom. The company has established research, development and manufacturing capabilities to support its gene therapy programs and has entered into collaborations with larger pharmaceutical companies, including Johnson & Johnson. Alexandria Forbes is a co-founder and has served as the company’s president and chief executive officer.View MeiraGTx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura DealCintas Raises Guidance as a Major Catalyst Moves Closer Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
